Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Arrowhead Pharmaceuticals  / Equity Bottom-Up

<ul><li>On January 6, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced preliminary results for the company's two obesity programs: ARO-INHBE and ARO-ALK7.</li><li>In combination with tirzepatide, ARO-INHBE doubled weight loss and tripled reductions in visceral fat, total fat, and liver fat compared to tirzepatide alone.</li><li>ARO-INHBE was well tolerated both as a monotherapy and in combination with tirzepatide.</li></ul>

On January 6, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced preliminary results for the company's two obesity programs: ARO-INHBE and ARO-ALK7.In combination with tirzepatide, ARO-INHBE doubled weight loss and tripled reductions in visceral fat, total fat, and liver fat compared to tirzepatide alone.ARO-INHBE was well tolerated both as a monotherapy and in combination with tirzepatide.

ARWR: Encouraging Early Data for Obesity Programs 